Drug intelligence / Profile preview

CYTER915

Development stage: Unknown
Lead developer: FibroBiologics
Modality: Cell Therapies

Overview

CYTER915 is an investigational cell therapy being developed by FibroBiologics for cancer immunotherapy. The approach involves T cell expansion and the use of stressed fibroblasts to promote dendritic cell maturation, aiming to enhance anti-tumor immune responses. As of April 2025, the drug remains in the discovery/preclinical stage with no reported clinical trial data or regulatory approvals. Its primary therapeutic area is neoplasms (cancers), and it represents a novel strategy leveraging fibroblast biology for oncology applications[1][2].

Beyond the preview

Go deeper on CYTER915.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYTER915.

Explore the full profile